Claims for Patent: 10,869,827

Summary for Patent: 10,869,827

Title:	Compositions and kits for the removal of irritating compounds from bodily surfaces
Abstract:	The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble.
Inventor(s):	Angel; Arturo J. (Santa Rosa, CA), Litle; Larry W. (Lee's Summit, MO), Bley; Keith R. (Menlo Park, CA), Wilcox; Allan L. (Mountain View, CA), Jamieson; Gene C. (Boulder Creek, CA), Muhammad; Naweed (Fremont, CA)
Assignee:	Averitas Pharma Inc. (Morristown, NJ)
Application Number:	16/581,102
Patent Claims:	1. A kit comprising: a) a first composition comprising capsaicin or a capsaicin analog; and b) a second composition for cleansing capsaicin from a bodily surface comprising: i) about 80 to about 99 percent w/w polyethylene glycol (PEG); and ii) about 0.1 to about 4.0 percent w/w polyacrylate thickening agent, wherein the second composition is aqueous and has a viscosity of between 100 to 8000 cps. 2. The kit of claim 1, wherein the second composition comprises about 84 to about 94 percent w/w polyethylene glycol (PEG). 3. The kit of claim 2, wherein the second composition further comprises a stabilizer. 4. The kit of claim 3, wherein the second composition further comprises a cooling agent. 5. The kit of claim 3, wherein the second composition comprises: a) about 87 to about 91 percent w/w polyethylene glycol (PEG); b) about 0.3 to about 2 percent w/w polyacrylate thickening agent; c) about 0.01 to about 0.03 percent w/w butylated hydroxyanisole; d) about 0.02 to about 0.2 percent w/w edetate sodium; and e) the balance water; wherein the second composition is at a pH of about 7.0 to about 7.7. 6. The kit of claim 5, wherein the second composition comprises: a) about 89.08 percent w/w PEG 300; b) about 1.0 percent w/w polyacrylate thickening agent; c) about 0.02 percent w/w butylated hydroxyanisole; d) about 0.1 percent w/w disodium edetate; and e) the balance water; wherein the second composition is at a pH of about 7.5. 7. The kit of claim 1, wherein the second composition has a pH between about 7.0 and about 7.7. 8. The kit of claim 1, wherein the second composition comprises about 90 percent w/w polyethylene glycol (PEG). 9. The kit of claim 8, wherein the second composition further comprises: a) about 0.1 to about 2.0 percent w/w polyacrylate thickening agent; and b) the balance water; wherein the second composition is at a pH between about 7.0 and about 7.7. 10. The kit of claim 1, wherein the PEG of the second composition is PEG 200 to PEG 600. 11. The kit of claim 1, wherein capsaicin has a solubility of at least about 10 to 25 percent w/w in the second composition. 12. The kit of claim 11, wherein capsaicin has a solubility of about 10 percent w/w in the second composition. 13. The kit of claim 11, wherein capsaicin has a solubility of about 20 percent w/w in the second composition. 14. The kit of claim 11, wherein capsaicin has a solubility of about 25 percent w/w in the second composition. 15. The kit of claim 1, wherein the second composition is a surfactant-free gel. 16. The kit of claim 1, wherein the viscosity of the second composition is between 4000 cps to 8000 cps. 17. The kit of claim 16, wherein the viscosity of the second composition is between 4000 to 5000 cps. 18. The kit of claim 1, wherein the viscosity of the second composition is between 2000 to 5000 cps. 19. The kit of claim 1, wherein the viscosity of the second composition is between 100 to 1000 cps. 20. The kit of claim 1, wherein the second composition is substantially free of particulates. 21. The kit of claim 1, wherein the polyacrylate thickening agent of the second composition is an acrylic acid/ethylacrylate copolymer or a carboxyvinyl polymer. 22. The kit of claim 1, wherein the first composition comprises the capsaicin or the capsaicin analog contained in a transdermal patch. 23. The kit of claim 22, wherein the capsaicin or the capsaicin analog is present in the transdermal patch at an amount of about 0.64 mg/cm.sup.2. 24. The kit of claim 22, wherein the capsaicin or the capsaicin analog is present in the transdermal patch in an amount of about 5% to about 10% by weight.